These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 11575043

  • 1. Preventive strategies for reducing coronary heart disease-related morbidity and mortality in patients with multiple risk factors.
    Brown WV.
    J Am Osteopath Assoc; 2001 Sep; 101(9 Suppl):S6-11. PubMed ID: 11575043
    [Abstract] [Full Text] [Related]

  • 2. Reducing the risk of coronary heart disease via lipid reduction.
    Spratt KA.
    J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S9-13. PubMed ID: 15467018
    [Abstract] [Full Text] [Related]

  • 3. Low-density lipoprotein cholesterol reduction: the end is more important than the means.
    LaRosa JC.
    Am J Cardiol; 2007 Jul 15; 100(2):240-2. PubMed ID: 17631077
    [Abstract] [Full Text] [Related]

  • 4. Effective use of statins to prevent coronary heart disease.
    Crouch MA.
    Am Fam Physician; 2001 Jan 15; 63(2):309-20, 323-4. PubMed ID: 11201696
    [Abstract] [Full Text] [Related]

  • 5. The new "lower is better" lipid goals: are they achievable with today's drugs?
    Chilton RJ.
    J Am Osteopath Assoc; 2002 May 15; 102(5 Suppl 1):S1-5. PubMed ID: 12046679
    [Abstract] [Full Text] [Related]

  • 6. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
    Ballantyne CM.
    Am J Cardiol; 2005 Nov 07; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009
    [Abstract] [Full Text] [Related]

  • 7. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.
    Stone NJ, Bilek S, Rosenbaum S.
    Am J Cardiol; 2005 Aug 22; 96(4A):53E-59E. PubMed ID: 16098845
    [Abstract] [Full Text] [Related]

  • 8. Optimal management of cholesterol levels and the prevention of coronary heart disease in women.
    Mosca LJ.
    Am Fam Physician; 2002 Jan 15; 65(2):217-26. PubMed ID: 11820486
    [Abstract] [Full Text] [Related]

  • 9. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Daskalopoulou SS, Kakafika AI, Pehlivanidis AN, Bouloukos VI, Langer A, GREACE Study Collaborative Group.
    Curr Med Res Opin; 2004 Sep 15; 20(9):1385-92. PubMed ID: 15383187
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Practicing effective preventive medicine. Pharmacologic interventions in coronary heart disease.
    Eisenberg DA.
    Postgrad Med; 2003 Apr 15; 113(4 Suppl):24-30. PubMed ID: 19667620
    [Abstract] [Full Text] [Related]

  • 12. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    J Am Coll Cardiol; 2004 Aug 04; 44(3):720-32. PubMed ID: 15358046
    [Abstract] [Full Text] [Related]

  • 13. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    Arterioscler Thromb Vasc Biol; 2004 Aug 04; 24(8):e149-61. PubMed ID: 15297292
    [Abstract] [Full Text] [Related]

  • 14. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S, Ridker PM.
    Am J Cardiol; 2006 Jan 16; 97(2A):33A-41A. PubMed ID: 16442935
    [Abstract] [Full Text] [Related]

  • 15. Statin therapy in South Asians-facts and future.
    Dalal P, Arora R.
    Am J Ther; 2010 Jan 16; 17(2):e41-7. PubMed ID: 19262368
    [Abstract] [Full Text] [Related]

  • 16. New evidence supporting aggressive lipid lowering.
    Stein EA.
    Postgrad Med; 2003 Apr 16; 113(4 Suppl):31-40. PubMed ID: 19667621
    [Abstract] [Full Text] [Related]

  • 17. Cholesterol and coronary events. The current thinking.
    Jones PH.
    Postgrad Med; 2003 Apr 16; 113(4 Suppl):5-14. PubMed ID: 19667618
    [Abstract] [Full Text] [Related]

  • 18. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Sever PS.
    Am J Med; 2005 Dec 16; 118 Suppl 12A():3-9. PubMed ID: 16356801
    [Abstract] [Full Text] [Related]

  • 19. Optimal medical management of peripheral arterial disease.
    Rice TW, Lumsden AB.
    Vasc Endovascular Surg; 2006 Dec 16; 40(4):312-27. PubMed ID: 16959725
    [Abstract] [Full Text] [Related]

  • 20. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH.
    Am J Cardiol; 2007 Nov 15; 100(10):1499-501. PubMed ID: 17996508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.